Norma Carmen
Gutiérrez Gutiérrez
Profesora Asociada CC. Salud
Hospital Universitario de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (189)
2024
-
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
Blood, Vol. 143, Núm. 7, pp. 597-603
-
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling
Haematologica, Vol. 109, Núm. 3, pp. 877-887
-
Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options
Journal of Clinical Medicine, Vol. 13, Núm. 1
2023
-
Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome
British Journal of Haematology, Vol. 200, Núm. 3, pp. 306-314
-
Multiple myeloma with t(11;14): impact of novel agents on outcome
Blood Cancer Journal, Vol. 13, Núm. 1
-
Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
Cancers, Vol. 15, Núm. 5
2022
-
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research
-
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma
American Journal of Hematology, Vol. 97, Núm. 6, pp. 700-710
-
Genomics of Plasma Cell Leukemia
Cancers, Vol. 14, Núm. 6
-
Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma
Archives of pathology & laboratory medicine, Vol. 146, Núm. 7, pp. 862-871
-
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
Cancers, Vol. 14, Núm. 20
-
RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation
Experimental Hematology and Oncology, Vol. 11, Núm. 1
-
TCL-318 Evaluation of the Antitumor Activity of Amiloride in Peripheral T-Cell Lymphomas Using In-Vitro Models
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S399
-
Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome
British Journal of Haematology, Vol. 199, Núm. 3, pp. 344-354
-
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
Blood cancer journal, Vol. 12, Núm. 4, pp. 76
2021
-
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival
British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852
-
Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
Cells, Vol. 10, Núm. 2
-
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
Blood Cancer Journal, Vol. 11, Núm. 5
-
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
Cells, Vol. 10, Núm. 3
2020
-
A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients
Journal of Molecular Diagnostics, Vol. 22, Núm. 1, pp. 60-71